

Publications for Nico van Zandwijk

2018

Jiang, T., Su, C., Ren, S., Cappuzzo, F., Rocco, G., Palmer, J., van Zandwijk, N., Blackhall, F., Le, X., Pennell, N., et al (2018). A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. *Journal of Thoracic Disease*, 10(7), 3909-3921. [More Information]

Schelch, K., Kirschner, M., Williams, M., Cheng, Y., van Zandwijk, N., Grusch, M., Reid, G. (2018). A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in Mesothelioma. *Molecular Oncology*, 12(1), 58-73. [More Information]

Linton, A., Cheng, Y., Griggs, K., Schedlich, L., Kirschner, M., Gattani, S., Srikanan, S., Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2018). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. *British Journal of Cancer*, 118(6), e13. [More Information]

Johnson, T., Schelch, K., Cheng, Y., Williams, M., Sarun, K., Kirschner, M., Kao, S., Linton, A., Klebe, S., McCaughan, B., Lin, R., van Zandwijk, N., Reid, G., et al (2018). Dysregulated expression of the microRNA miR-137 and its target YB-1 contribute to the invasive characteristics of malignant pleural mesothelioma. *Journal of Thoracic Oncology*, 13(2), 258-272. [More Information]

Schelch, K., Wagner, C., Hager, S., Pirker, C., Siess, K., Lang, E., Lin, R., Kirschner, M., Mohr, T., Brcic, L., Reid, G., van Zandwijk, N., et al (2018). FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. *Carcinogenesis*, 39(4), 534-545. [More Information]

van Zandwijk, N., McDiarmid, J., Brahmabhatt, H., Reid, G. (2018). Response to "An innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)". *Translational Lung Cancer Research*, 7(Supp 1), S60-S61. [More Information]

2017

Gulati, S., Mulshine, J., van Zandwijk, N. (2017). Chemoprevention of Lung Cancer and Management of Early Lung Cancer. In David Ball, & Giorgio V. Scagliotti (Eds.), *IASLC Thoracic Oncology, 2nd ed.* Philadelphia: Elsevier.

Odgerel, C., Takahashi, K., Sorahan, T., Driscoll, T., Fitzmaurice, C., Yoko-o, M., Sawanyawisuth, K., Furuya, S., Tanaka, F., Horie, S., van Zandwijk, N., et al (2017). Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. *Occupational and Environmental Medicine*, 74(12), 851-858. [More Information]

Linton, A., Soeberg, M., Broome, R., Kao, S., van Zandwijk, N. (2017). Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes. *Respirology*, 22(5), 978-985. [More Information]

Meyer, M., Vliegthart, R., Henzler, T., Buegy, D., Giordano, F., Kostrzewa, M., Rathmann, N., Brustugun, O., Crino, L., Dingemans, A., van Zandwijk, N., et al (2017). Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies. *Journal of Thoracic Oncology*, 12(12), 1755-1765. [More Information]

van Zandwijk, N., Pavlakis, N., Kao, S., Linton, A., Boyer, M., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M., Bailey, D., Cooper, W., Kritharides, L., Reid, G., et al (2017). Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. *The Lancet Oncology*, 18(10), 1386-1396. [More Information]

Winata, P., Williams, M., McGowan, E., Nassif, N., van Zandwijk, N., Reid, G. (2017). The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection. *BMC Research Notes*, 10(1), 1-7. [More Information]

Manegold, C., Dingemans, A., Grey, J., Nakagawa, K., Nicolson, M., Peters, S., Reck, M., Wu, Y., Brustugun, O., van Zandwijk, N., et al (2017). The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. *Journal of Thoracic Oncology*, 12(2), 194-207. [More Information]

Kao, S., Cheng, Y., Williams, M., Kirschner, M., Madore, J., Lum, T., Sarun, K., Linton, A., McCaughan, B., Klebe, S., van Zandwijk, N., Scolyer, R., Boyer, M., Cooper, W., Reid, G. (2017). Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, 12(9), 1421-1433. [More Information]

2016

Kao, S., Kirschner, M., Cooper, W., Tran, T., Burgers, S., Wright, C., Korse, T., van den Broek, D., Edelman, J., Vallely, M., McCaughan, B., Pavlakis, N., Clarke, S., van Zandwijk, N., Reid, G., et al (2016). A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. *British Journal of Cancer*, 114(5), 524-531. [More Information]

Soeberg, M., van Zandwijk, N. (2016). Asbestos and malignant pleural mesothelioma. In T C Mineo (Eds.), *Malignant Pleural*

Mesothelioma: Present Status and Future Directions, (pp. 115-128). Sharjah: Bentham eBooks - imprint of Bentham Science Publishers. [More Information]

Hoda, M., Dong, Y., Rozsas, A., Klikovits, T., Laszlo, V., Ghanim, B., Stockhammer, P., Ozsvar, J., Jakopovic, M., Reid, G., van Zandwijk, N., et al (2016). Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. *European Journal of Cancer*, 63, 64-73. [More Information]

Reid, G., Kao, S., Pavlakis, N., Brahmabhatt, H., MacDiarmid, J., Clarke, S., Boyer, M., van Zandwijk, N. (2016). Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. *Epigenomics*, 8(8), 1079-1085. [More Information]

Soeberg, M., Luong, M., Van Tran, T., Tran, A., Nguyen, T., Bui, D., Nguyen, T., Takahashi, K., van Zandwijk, N. (2016). Estimating the incidence of malignant mesothelioma in Vietnam: A pilot descriptive cancer registration study. *International Journal of Occupational and Environmental Health*, 22(2), 167-172. [More Information]

Soeberg, M., Leigh, J., Driscoll, T., Armstrong, B., Young, J., van Zandwijk, N. (2016). Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009. *Occupational and Environmental Medicine*, 73(3), 187-194. [More Information]

Cheng, Y., Wright, C., Kirschner, M., Williams, M., Sarun, K., Sytnyk, V., Leshchynska, I., Edelman, J., Vallely, M., McCaughan, B., van Zandwijk, N., Reid, G., et al (2016). KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. *Molecular Cancer*, 15(1), 1-12. [More Information]

Soeberg, M., Leigh, J., van Zandwijk, N. (2016). Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends. *Journal of Toxicology and Environmental Health. Part B: Critical Reviews*, 19(5-6), 173-189. [More Information]

Lin, R., Kirschner, M., Cheng, Y., van Zandwijk, N., Reid, G. (2016). MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. *Genomics Data*, 9, 44-49. [More Information]

Soeberg, M., Creighton, N., Currow, D., Young, J., van Zandwijk, N. (2016). Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009. *Australian and New Zealand Journal of Public Health*, 40(3), 255-262. [More Information]

Fong, K., van Zandwijk, N. (2016). Update in lung cancer: epilogue to a modern review series. *Respirology*, 21(5), 789-790. [More Information]

van Zandwijk, N., Soeberg, M., Reid, G. (2016). Using a

multidisciplinary approach to combat the burden of asbestos-related disease. *Medical Journal of Australia*, 204(2), 52-52.e1. [More Information]

2015

Kao, S., Fulham, M., Wong, K., Cooper, W., Brahmabhatt, H., MacDiarmid, J., Pattison, S., Sagong, J., Huynh, Y., Leslie, F., Pavlakis, N., Clarke, S., Boyer, M., Reid, G., van Zandwijk, N. (2015). A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. *American Journal of Respiratory and Critical Care Medicine*, 191(12), 1467-1469. [More Information]

Kao, S., van Zandwijk, N., Clarke, S., Vardy, J., Lumba, S., Tognela, A., Ng, W. (2015). Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care. *Asia-Pacific Journal of Clinical Oncology*, 11, 85-92. [More Information]

Kirschner, M., Emily, P., Hoda, M., Rozsas, A., Griggs, K., Cheng, Y., Edelman, J., Kao, S., Hyland, R., Dong, Y., Vallely, M., van Zandwijk, N., Reid, G., et al (2015). Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. *British Journal of Cancer*, 113(6), 963-969. [More Information]

Soeberg, M., van Zandwijk, N. (2015). Incidence of malignant mesothelioma in New Zealand and Australia: A global snapshot. *New Zealand Medical Journal*, 128(1427), 68-71.

Lin, R., van Zandwijk, N., Reid, G. (2015). MicroRNA Therapeutics ½ Back in Vogue? *Journal of Investigative Genomics*, 2(1), 12.

Williams, M., Kirschner, M., Cheng, Y., Hanh, J., Weiss, J., Amaro-Mugridge, N., Wright, C., Linton, A., Kao, S., Edelman, J., Vallely, M., Cooper, W., van Zandwijk, N., Reid, G., et al (2015). miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. *Oncotarget*, 6(27), 23480-23495. [More Information]

Kirschner, M., Cheng, Y., Armstrong, N., Lin, R., Kao, S., Linton, A., Klebe, S., McCaughan, B., van Zandwijk, N., Reid, G. (2015). MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. *Molecular Oncology*, 9(3), 715-726. [More Information]

Kumarakulasinghe, N., van Zandwijk, N., Soo, R. (2015). Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). *Respirology*, 20(3), 370-378. [More Information]

van Zandwijk, N., Fong, K. (2015). Update in lung cancer: Prologue to a modern review series. *Respirology*, 20(2), 183-184. [More Information]

2014

Linton, A., Cheng, Y., Griggs, K., Kirschner, M., Gattani, S., Srikanan, S., Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2014). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant

pleural mesothelioma. *British Journal of Cancer*, 110(2), 510-519. [More Information]

Cheng, N., van Zandwijk, N., Reid, G. (2014). Cilengitide Inhibits Attachment and Invasion of Malignant Pleural Mesothelioma Cells through Antagonism of Integrins $\alpha_5\beta_1$ and $\alpha_v\beta_3$. *PLoS One*, 9(3), 1-10. [More Information]

Kao, S., van Zandwijk, N., Clarke, S. (2014). Comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'. *British Journal of Cancer*, 111(12), 2376-2376. [More Information]

Linton, A., Pavlakis, N., O'Connell, R., Soeberg, M., Kao, S., Clarke, S., Vardy, J., van Zandwijk, N. (2014). Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. *British Journal of Cancer*, 111(9), 1860-1869. [More Information]

2013

Kirschner, M., van Zandwijk, N., Reid, G. (2013). Cell-free microRNAs: potential biomarkers in need of standardized reporting. *Frontiers in Genetics*, 4, 1-5. [More Information]

Henderson, D., Reid, G., Kao, S., Van Zandwijk, N., Klebe, S. (2013). Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. *Journal of Clinical Pathology*, 66(10), 854-861. [More Information]

Henderson, D., Reid, G., Kao, S., Van Zandwijk, N., Klebe, S. (2013). Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. *Journal of Clinical Pathology*, 66(10), 847-853. [More Information]

van Zandwijk, N. (2013). Clinical practice guidelines for malignant pleural mesothelioma. *Journal of Thoracic Disease*, 5(6), 724-725. [More Information]

Wright, C., Kirschner, M., van Zandwijk, N., Reid, G. (2013). Does miR-1 play a role in malignant pleural mesothelioma development and progression? *Chest*, 144(6), 1971. [More Information]

Kao, S., Lee, K., Klebe, S., Henderson, D., McCaughan, B., Vardy, J., Clarke, S., van Zandwijk, N. (2013). Excision Repair Cross Complementation Group 1 and Thymidylate Synthase Expression in Patients With Mesothelioma. *Clinical Lung Cancer*, 14(2), 164-171. [More Information]

van Zandwijk, N., Clarke, C., Henderson, D., Musk, A., Fong, K., Nowak, A., Loneragan, R., McCaughan, B., Boyer, M., Feigen, M., et al (2013). Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. *Journal of*

Thoracic Disease, 5(6), E254-E307. [More Information]

Kao, S., Vardy, J., Harvie, R., Chatfield, M., van Zandwijk, N., Clarke, S., Pavlakis, N. (2013). Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. *Supportive Care in Cancer*, 21(3), 697-705. [More Information]

Majewski, I., Mittempergher, L., Davidson, N., Bosma, A., Willems, S., Horlings, H., de Rink, I., Greger, L., Hooijer, G., Van Zandwijk, N., et al (2013). Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. *Journal of Pathology*, 230(3), 270-276. [More Information]

Linton, A., Kao, S., Vardy, J., Clarke, S., van Zandwijk, N., Klebe, S. (2013). Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review. *Asia-Pacific Journal of Clinical Oncology*, 9(3), 273-279. [More Information]

Wright, C., Kirschner, M., Cheng, Y., O'Byrne, K., Gray, S., Schelch, K., Hoda, M., Klebe, S., McCaughan, B., van Zandwijk, N., Reid, G. (2013). Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). *PLoS One*, 8(8), 1-12. [More Information]

Honeyball, F., Boyer, M., van Zandwijk, N., Kao, S. (2013). Malignant pleural mesothelioma. *Cancer Forum*, 37(2), 181-185.

Kao, S., Clarke, S., Vardy, J., Corte, P., Clarke, C., van Zandwijk, N. (2013). Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. *Internal Medicine Journal*, 43(4), 402-410. [More Information]

Reid, G., Pel, M., Kirschner, M., Cheng, Y., Amaro-Mugridge, N., Madrid-Weiss, J., Williams, M., Wright, C., Edelman, J., Vallely, M., van Zandwijk, N., et al (2013). Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. *Annals of Oncology*, 24(12), 3128-3135. [More Information]

Kirschner, M., Edelman, J., Kao, S., Vallely, M., van Zandwijk, N., Reid, G. (2013). The Impact of Hemolysis on Cell-Free microRNA Biomarkers. *Frontiers in Genetics*, 4, 1-13. [More Information]

Kao, S., van Zandwijk, N., Corte, P., Clarke, C., Clarke, S., Vardy, J. (2013). Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. *Supportive Care in Cancer*, 21(7), 1879-1884. [More Information]

Kao, S., Vardy, J., Chatfield, M., Corte, P., Pavlakis, N., Clarke, C., van Zandwijk, N., Clarke, S. (2013). Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board. *Clinical Lung Cancer*, 14(1), 70-77. [More Information]

Information]

Cheng, Y., Kirschner, M., Cheng, N., Gattani, S., Klebe, S., Edelman, J., Vallely, M., McCaughan, B., Jin, H., van Zandwijk, N., Reid, G. (2013). ZIC1 Is Silenced and Has Tumor Suppressor Function in Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, 8(10), 1317-1328. [More Information]

2012

Manegold, C., van Zandwijk, N., Szczesna, A., Zatloukal, P., Au, J., Blasinska-Morawiec, M., Serwatowski, P., Krzakowski, M., Jassem, J., Tan, E., et al (2012). A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. *Annals of Oncology*, 23(1), 72-77. [More Information]

Kirschner, M., Cheng, Y., Badrian, B., Kao, S., Creaney, J., Edelman, J., Armstrong, N., Vallely, M., Musk, A., Robinson, B., McCaughan, B., van Zandwijk, N., Reid, G., et al (2012). Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, 7(7), 1184-1191. [More Information]

Linton, A., van Zandwijk, N., Reid, G., Clarke, S., Cao, C., Kao, S. (2012). Inflammation in malignant mesothelioma - friend or foe? *Annals of Cardiothoracic Surgery*, 1(4), 516-522. [More Information]

van Zandwijk, N., Reid, G., Linton, A., Kao, S. (2012). Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools? *Annals of Cardiothoracic Surgery*, 1(4), 481-486. [More Information]

Linton, A., Vardy, J., Clarke, S., van Zandwijk, N. (2012). The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma. *Critical Reviews in Oncology / Hematology (online)*, 84(2), 200-212. [More Information]

2011

Kao, S., Yan, T., Lee, K., Burn, J., Henderson, D., Klebe, S., Kennedy, C., Vardy, J., Clarke, S., Van Zandwijk, N., et al (2011). Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. *Journal of Thoracic Oncology*, 6(3), 602-605. [More Information]

Schaake, E., Aukema, T., Belderbos, J., Uyterlinde, W., van Zandwijk, N., Valdes Olmos, R., Verheij, M., Vincent, A., Van den Heuvel, M. (2011). Cetuximab in combination with single agent daily cisplatin chemotherapy concurrent with radiotherapy in locally advanced nonsmall cell lung carcinoma: A feasibility study. *European Journal of Clinical & Medical Oncology*, 3(3), 65-71.

Reid, G., Kirschner, M., van Zandwijk, N. (2011). Circulating microRNAs: Association with disease and potential use as biomarkers. *Critical Reviews in Oncology/Hematology*, 80(2), 193-208. [More Information]

Kirschner, M., Kao, S., Edelman, J., Armstrong, N., Vallely, M., van Zandwijk, N., Reid, G. (2011). Haemolysis during Sample Preparation Alters microRNA Content of Plasma. *PLoS One*, 6(9), 1-9. [More Information]

Kao, S., Klebe, S., Henderson, D., Reid, G., Chatfield, M., Armstrong, N., Yan, T., Vardy, J., Clarke, S., van Zandwijk, N., McCaughan, B. (2011). Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy. *Journal of Thoracic Oncology*, 6(11), 1923-1929. [More Information]

Kao, S., Reid, G., van Zandwijk, N., Henderson, D., Klebe, S. (2011). Molecular biomarkers in malignant mesothelioma: state of the art. *Pathology*, 43(3), 201-212. [More Information]

Heigener, D., Wu, Y., van Zandwijk, N., Mali, P., Horwood, K., Reck, M. (2011). Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. *Lung Cancer*, 74(2), 274-279. [More Information]

Weder, W., Stahel, R., Baas, P., Dafni, U., de Perrot, M., McCaughan, B., Nakano, T., Robinson, B., van Zandwijk, N., et al (2011). The MARS feasibility trial: conclusions not supported by data. *The Lancet Oncology*, 12(12), 1093-1094. [More Information]

Kao, S., Griggs, K., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Burn, J., McCaughan, B., Henderson, D., et al (2011). Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. *Pathology*, 43(4), 313-317. [More Information]

Kao, S., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Reid, G., Burn, J., McCaughan, B., Henderson, D., et al (2011). Validation of tissue microarray technology in malignant pleural mesothelioma. *Pathology*, 43(2), 128-132. [More Information]

2010

Reck, M., van Zandwijk, N., Gridelli, C., Baliko, Z., Rischin, D., Allan, S., Krzakowski, M., Heigener, D. (2010). Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study. *Journal of Thoracic Oncology*, 5(10), 1616-1622. [More Information]

Kao, S., Pavlakakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. *Clinical Cancer Research*, 16(23), 5805-5813. [More Information]

Kao, S., Reid, G., Lee, K., Vardy, J., Clarke, S., van Zandwijk, N. (2010). Malignant Mesothelioma. *International Medical Journal*. [More Information]

href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20298508">[More Information]

Kappers, I., van Sandick, J., Burgers, S., Belderbos, J., van Zandwijk, N., Klomp, H. (2010). Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: Why pneumonectomy should be avoided. *Lung Cancer*, 68(2), 222-227. [More Information]

2009

Roepman, P., Jassem, J., Smit, E., Muley, T., Niklinski, J., van de Velde, T., Witteveen, A., Ryzman, W., Floore, A., Burgers, S., van Zandwijk, N., et al (2009). An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non-Small-Cell Lung Cancer. *Clinical Cancer Research*, 15(1), 284-290. [More Information]

Geurts, T., van Velthuysen, M., Broekman, F., Hoof van Huysduynen, T., van den Brekel, M., van Zandwijk, N., van Tinteren, H., Nederlof, P., Balm, A., Brakenhoff, R. (2009). Differential Diagnosis of Pulmonary Carcinoma Following Head and Neck Cancer by Genetic Analysis. *Clinical Cancer Research*, 15(3), 980-985. [More Information]

Van den Heuvel, M., Burgers, S., van Zandwijk, N. (2009). Immunotherapy in Non-Small-Cell Lung Carcinoma: From Inflammation to Vaccination. *Clinical Lung Cancer*, 10(2), 99-105. [More Information]

van Zandwijk, N. (2009). Individualization of treatment in non-small cell lung cancer. *F1000 Medicine Reports*, 2009 (1:24). [More Information]

van Zandwijk, N. (2009). Lung cancer: oncogenesis and prevention. In S G Spiro, R M Huber, S M Janes (Eds.), *Thoracic Malignancies*, (pp. 1-14). Plymouth: European Respiratory Society.

Smit, E., Burgers, S., Biesma, B., Smit, H., Eppinga, P., Dingemans, A., Joerger, M., Schellens, J., Vincent, A., van Zandwijk, N., et al (2009). Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, 27(12), 2038-2045. [More Information]

Smit, E., Groen, H., van Zandwijk, N. (2009). Reply to L.H. de Lima Araujo et al. *Journal of Clinical Oncology*, 28(2), e26-e26. [More Information]

Kappers, I., van Sandick, J., Burgers, J., Belderbos, J., Wouters, M., van Zandwijk, N., Klomp, H. (2009). Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. *European Journal Of Cardio-Thoracic Surgery*, 36(4), 741-746. [More Information]

Geurts, T., Balm, A., van Velthuysen, M., van Tinteren, H., Burgers, J., van Zandwijk, N., Klomp, H. (2009). Survival after surgical resection of pulmonary metastases and second primary

squamous cell lung carcinomas in head and neck cancer. *Head and Neck*, 31(2), 220-226. [More Information]

2008

van den Berg, R., Teertstra, H., van Zandwijk, N., van Tinteren, H., Visser, C., Pasic, A., Sutedja, T., Baas, P., Golding, R., Postmus, P., et al (2008). CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. *Lung Cancer*, 60(1), 57-61. [More Information]

Ruiz, M., Floor, K., Roepman, P., Rodriguez, J., Meijer, G., Mooi, W., Jassem, E., Niklinski, J., Muley, T., van Zandwijk, N., et al (2008). Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. *PloS One*, 3(3), e1722 - 1-e1722 - 8. [More Information]

Kappers, I., Klomp, H., Burgers, J., van Zandwijk, N., Haas, R., van Pel, R. (2008). Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. *Journal of Clinical Oncology*, 26(25), 4205-4207. [More Information]

Kappers, I., Belderbos, J., Burgers, J., van Zandwijk, N., Groen, H., Klomp, H. (2008). Non-small cell lung carcinoma of the superior sulcus: favourable outcomes of combined modality treatment in carefully selected patients. *Lung Cancer*, 59(3), 385-390. [More Information]

2007

van Zandwijk, N., van de Vijver, M. (2007). Clairvoyance or reliable prediction of the future? *Annals of Oncology*, 18(3), 407-8. [More Information]

van Zandwijk, N., Mathy, L., Boerrigter, L., Ruitjer, H., Tielen, I., de Jong, D., Baas, P., Burgers, S., Nederlof, P. (2007). EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. *Annals of Oncology*, 18(1), 99-103. [More Information]

Zuur, J., Muller, S., Sinaasappel, M., Hart, G., van Zandwijk, N., Hilgers, F. (2007). Influence of heat and moisture exchanger respiratory load on transcutaneous oxygenation in laryngectomized individuals: A randomized crossover study. *Head and Neck*, 29(12), 1102-1110. [More Information]

Kartachova, M., van Zandwijk, N., Burgers, S., van Tinteren, H., Verheij, M., Valdes Olmos, R. (2007). Prognostic Significance of 99mTc Hynic-rh-Annexin V Scintigraphy During Platinum-Based Chemotherapy in Advanced Lung Cancer. *Journal of Clinical Oncology*, 25(18), 2534-2539. [More Information]

Belderbos, J., Uitterhoeve, L., van Zandwijk, N., Belderbos, H., Rodrigus, P., van de Vaart, P., Legrand, C., Dussenne, S., Bartelink, H., Giaccone, G., et al (2007). Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-

22973). *European Journal of Cancer*, 43(1), 114-121. [More Information]

van Meerbeeck, J., Kramer, G., van Schil, P., Legrand, C., Smit, E., Schramel, F., Tjan-Heijnen, V., Biesma, B., Debruyne, C., van Zandwijk, N., et al (2007). Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. *Journal of the National Cancer Institute*, 99(6), 442-450. [More Information]

van den Berg, R., van Tinteren, H., van Zandwijk, N., Visser, C., Pasic, A., Kooi, C., Sutudja, T., Baas, P., GrÅ¼nberg, K., Mooi, W., et al (2007). The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epithelium. *American Journal of Respiratory and Critical Care Medicine*, 175(10), 1061-1065. [More Information]

2006

Scagliotti, G., Szczesna, A., Ramlau, R., Cardenal, F., Mattson, K., Van Zandwijk, N., Price, A., Lebeau, B., Debus, J., Manegold, C. (2006). Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. *British Journal of Cancer*, 94(10), 1375-1382. [More Information]

van Zandwijk, N. (2006). Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics. *Lung Cancer*, 51(1), 137-138. [More Information]

Kartachova, M., Valdes Olmos, R., Haas, R., Hoebbers, F., van den Brekel, M., van Zandwijk, N., van Herk, M., Verheij, M. (2006). Mapping of treatment-induced apoptosis in normal structures: 99mTc-Hynic-rh-annexin V SPECT and CT image fusion. *European Journal of Nuclear Medicine and Molecular Imaging*, 33(8), 893-899. [More Information]

Kramer, G., Legrand, C., van Schil, P., Uitterhoeve, L., Smit, E., Schramel, F., Biesma, B., Tjan-Heijnen, V., van Zandwijk, N., Splinter, T., et al (2006). Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. *European Journal of Cancer*, 42(10), 1391-1398. [More Information]

Rademaker-Lakhai, J., Crul, M., Zuur, L., Baas, P., Beijnen, J., Simis, Y., van Zandwijk, N., Schellens, J. (2006). Relationship Between Cisplatin Administration and the Development of Ototoxicity. *Journal of Clinical Oncology*, 24(6), 918-924. [More Information]

Yohannes, K., Muller, S., de Jongh, F., van Zandwijk, N., Hilgers, F. (2006). The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. *European Archives of Oto-Rhino-Laryngology*, 263(1), 1-8. [More Information]

Geurts, T., Ackerstaff, A., van Zandwijk, N., Hart, A., Hilgers, F., Balm, A. (2006). The psychological impact of annual chest X-ray follow-up in head and neck cancer. *Acta Oto-*

Laryngologica, 126(12), 1315-1320. [More Information]

2005

van Zandwijk, N. (2005). Chemoprevention in lung carcinogenesis--an overview. *European Journal of Cancer*, 41(13), 1990-2002. [More Information]

Le Chevalier, T., Scagliotti, G., Natale, R., Danson, S., Rosell, R., Stahel, R., Thomas, P., Rudd, R., Vansteenkiste, J., Thatcher, N., van Zandwijk, N., et al (2005). Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. *Lung Cancer*, 47(1), 69-80. [More Information]

Mathy, A., Baas, P., Dalesio, O., van Zandwijk, N. (2005). Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. *Lung Cancer*, 50(1), 83-86. [More Information]

van Schil, P., van Meerbeeck, J., Kramer, G., Splinter, T., Legrand, C., Giaccone, G., Manegold, C., van Zandwijk, N. (2005). Morbidity and mortality in the surgery arm of EORTC 08941 trial. *European Respiratory Journal*, 26(2), 192-197. [More Information]

Rademaker-Lakhai, J., Crul, M., Pluim, D., Sparidans, R., Baas, P., Beijnen, J., van Zandwijk, N., Schellens, J. (2005). Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. *Anti-Cancer Drugs*, 16(9), 1029-1036. [More Information]

Hoekstra, C., Stroobants, S., Smit, E., Vansteenkiste, J., van Tinteren, H., Postmus, P., Golding, R., Biesma, B., Schramel, F., van Zandwijk, N., et al (2005). Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients with Locally Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, 23(33), 8362-8370. [More Information]

Geurts, T., Nederlof, P., van den Brekel, M., van't Veer, L., de Jong, D., Hart, A., van Zandwijk, N., Klomp, H., Balm, A., van Velthuysen, M. (2005). Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? *Clinical Cancer Research*, 11(18), 6608-6614. [More Information]

Baas, P., Boogerd, W., Dalesio, O., Haringhuizen, A., Custers, F., van Zandwijk, N. (2005). Thalidomide in patients with malignant pleural mesothelioma. *Lung Cancer*, 48(2), 291-296. [More Information]

Koning, C., van Zandwijk, N. (2005). Two patients with advanced non-small cell lung cancer (stage IIIB) who still responded very well to combined chemotherapy and radiotherapy. *Nederlands Tijdschrift voor Geneeskunde*, 149(23), 1289-1293.

eve&db=pubmed&dopt=Abstract&list_uids=15960136">[More Information]

2004

de Jonge, M., van den Bongard, H., Huitema, A., MathÃ´t, R., Rosing, H., Baas, P., van Zandwijk, N., Beijnen, J., Schellens, J. (2004). Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. *Clinical Cancer Research*, 10(7), 2237-2244. [More Information]

Haringhuizen, A., van Tinteren, H., Vaessen, H., Baas, P., van Zandwijk, N. (2004). Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. *Annals of Oncology*, 15(5), 786-792. [More Information]

Kartachova, M., Haas, R., Valdes Olmos, R., Hoebbers, F., van Zandwijk, N., Verheij, M. (2004). In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. *Radiotherapy and Oncology*, 72(3), 333-339. [More Information]

Gatzemeier, U., Groth, G., Butts, C., van Zandwijk, N., Shepherd, F., Ardizzoni, A., Barton, C., Ghahramani, P., Hirsh, V. (2004). Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. *Annals of Oncology*, 15(1), 19-27. [More Information]

Gridelli, C., Ardizzoni, A., Le Chevalier, T., Manegold, C., Perrone, F., Thatcher, N., van Zandwijk, N., Di Maio, M., Martelli, O., De Marinis, F. (2004). Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. *Annals of Oncology*, 15(3), 419-426. [More Information]

2003

Schellens, J., Planting, A., van Zandwijk, N., Ma, J., Maliepaard, M., van der Burg, M., de Boer-Denner, M., Brouwer, E., van der Gaast, A., van den Bent, M., et al (2003). Adaptive inpatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer. *British Journal of Cancer*, 88(6), 814-821. [More Information]

Crul, M., Schoemaker, N., Pluim, D., Maliepaard, M., Underberg, R., Schot, M., Sparidans, R., Baas, P., Beijnen, J., van Zandwijk, N., et al (2003). Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. *Clinical Cancer Research*, 9(10), 3526-3533. [More Information]

Baas, P., Ardizzoni, A., Grossi, F., Nackaerts, K., Numico, G., van Marck, E., van de Vijver, M., Monetti, F., Smid-Geirnaerdt, M., van Zandwijk, N., et al (2003). The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). *European Journal of Cancer*, 39(3), 353-357. [More Information]

Hoekstra, C., Stroobants, S., Hoekstra, O., Vansteenkiste, J., Biesma, B., Schramel, F., van Zandwijk, N., van Tinteren, H., Smit, E. (2003). The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. *Lung Cancer*, 39(2), 151-157. [More Information]

Schouwink, J., Kool, L., Rutgers, E., Zoetmulder, F., van Zandwijk, N., van de Vijver, M., Baas, P. (2003). The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. *The Annals of Thoracic Surgery*, 75(6), 1715-1718. [More Information]

van Zandwijk, N. (2003). Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. *British Journal of Cancer*, 89(suppl 2), S9-S14. [More Information]